Haleon plc: Notice of Annual General Meeting (AGM)
4 April 2025: Haleon plc (the "Company" or "Haleon") today announces that the following documents have been made available to shareholders:
1. Notice of 2025 Annual General Meeting (the "Notice");
2. Form of Proxy for 2025 Annual General Meeting; and
3. AGM Voting Instruction Card.
Haleon's AGM will again be a virtual meeting, broadcast under studio conditions from the Company's London offices at 3.00pm (BST) on Wednesday 28 May 2025. The Notice is available on the Company's website at https://www.haleon.com/investors/shareholder-information/annual-general-meetings, and includes full details of the business to be conducted and joining instructions.
In compliance with UK Listing Rule 6.4.1R, a copy of the above documents has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Amanda Mellor
Company Secretary
Enquiries
| Investors | Media
| ||
| Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
| Emma White | +44 7823 523562 | |
|
|
|
Email: corporate.media@haleon.com | ||
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.